Screening for cardiac amyloidosis in patients with new conduction disease at the Alfred (ACTRN12624000520538)

Previously thought of as a very rare condition, cardiac amyloidosis is increasingly being recognised as a cause of heart failure. Cardiac amyloidosis is caused by proteins depositing into the heart, leading to scarring. If this scarring occurs in the electrical system of the heart, the patient may require a pacemaker. It is currently unknown what proportion of patients that require pacemakers have cardiac amyloidosis. This trial is trying to determine the prevalence of cardiac amyloidosis in patients requiring pacemakers.

Trial phase

Other

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

A/Prof James Hare

Key inclusion data

INCLUSION: Patients aged 60 years or older with conduction disease requiring a pacemaker and at least 1 red flag for cardiac amyloidosis: History of carpal tunnel syndrome, low voltage ECG, increased LV wall thickness, moderate to severe aortic stenosis or unexplained elevation in proBNP and troponin. EXCLUSION: Patients with a clear alternative cause of conduction disease including other infiltrative cardiomyopathies, ischaemia or medication induced conduction disease. Patients with life expectancy < 24 months or severe comorbidities where screening would not be beneficial for the individual.